eligibility_summary
Adults ≥18 with R/R aggressive B‑cell NHL (MCL, LBCL: DLBCL, PMBCL, HGBCL, t‑FL, FL3B, Richter’s), FDG‑avid measurable disease, ECOG 0–1, adequate organs, prior chemo incl alkylator, anthracycline, anti‑CD20, and auto‑HSCT and CD19 CAR‑T unless ineligible/refused. Exclude: prior ROR1, need immunosuppression or cannot hold anticoag, CNS disease, major CV disease, HIV/HBV/HCV, recent fungal infection, residual COVID lung, other cancers <2 y, serious autoimmune, prior allo‑HSCT/organ tx.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
NCT05588440 tested ONCT-808, an autologous ROR1-directed CAR-T cell therapy (cellular immunotherapy) for relapsed/refractory aggressive B‑cell malignancies (LBCL, MCL). Patients received lymphodepletion with cyclophosphamide (alkylating cytotoxic agent) and fludarabine (purine analog antimetabolite) to enhance CAR‑T expansion, bridging chemo/radiotherapy was permitted. Mechanism: patient T cells are engineered with a CAR that binds ROR1, triggering T‑cell activation (CD3ζ/costimulation), proliferation, cytokine release, and perforin/granzyme‑mediated lysis of ROR1+ malignant B cells. Targets: ROR1 on tumor B cells (non‑canonical Wnt signaling axis) and T‑cell effector pathways. Study was terminated.